Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 3

3(42.9%)

Phase 2

1(14.3%)

7Total

Phase 1(3)

Phase 3(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00223080Phase 3Completed

HIV Vaccine Trial in Thai Adults

Role: collaborator

NCT00103584Phase 1Unknown

Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers

Role: lead

NCT00100724Phase 2Completed

Trial of rPA-102 Vaccine in Healthy Adult Volunteers

Role: lead

NCT00006327Phase 3Completed

Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand

Role: lead

NCT00002441Phase 3Completed

Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection

Role: lead

NCT00002402Phase 1Completed

A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines

Role: lead

NCT00103467Phase 1Completed

Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine

Role: lead

All 7 trials loaded